Data & Analytics

Creatv Bio will present data at ASCO 2026 on its LifeTracDx® blood test, showcasing its potential to personalize cancer treatment through key pharma partnerships.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.

Saudi Insurtech leader Rasan reports historic Q1 earnings, signaling deep alignment with Vision 2030 and a new era of fintech hyper-growth in the Kingdom.

New audits uncover that up to 40% of dental ad budgets are wasted on irrelevant clicks, prompting an urgent call for transparency from marketing agencies.

A startup's partnership with industry giant Alcon promises to make vision assessment faster, more precise, and accessible to patients everywhere.

With $2.5M in seed funding, Hamilton's Stoked Bio is using a novel AI platform to tackle the world's toughest diseases, from superbugs to brain cancer.

Once a photography giant, Fujifilm's pivot to healthcare and tech has earned it a top spot on TIME's Most Influential list. Here’s the story of its rebirth.

For the first time, Canada's biggest cities are shrinking. New data reveals where people are going and what it means for every business and community.

U.S. health tech giant Inovalon joins the World Economic Forum, aiming to leverage its massive data platform to combat a looming global health worker shortage.

With a $105M IPO, ARC Group Acquisition I Corp joins a recovering SPAC market, targeting tech, healthcare, and logistics with a veteran leadership team.

With $5M in new funding and key regulatory validation, Sapho Bio's rapid sterility test promises to slash drug release times and speed medicines to patients.

Swedish firm Navinci launches its Omni kit, targeting the spatial interactomics market with a new tool to visualize protein networks directly in tissue.

The world's largest mobile personal training franchise is rapidly expanding, fueled by consumer demand for convenience and a powerful new app.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

A landmark study reveals a hidden genetic cause for a common kidney disease in adults, urging for expanded genetic screening and paving the way for new therapies.

With its Q1 2026 results imminent, the parent of Betway and Spin faces scrutiny to see if its global strategy can uphold its stellar financial momentum.

Ascidian Therapeutics to present first human safety data for its Stargardt disease drug, a new RNA editing technology with broad potential for genetic diseases.

Global property giant Goodman Group is buying back over $396M in debt. We explore the strategy behind this move and what it signals for the industry.

A UK firm's breakthrough blood test for early breast cancer detection joins a prestigious EU network, aiming to personalize treatment and redefine diagnostics.

The firm known for property-level climate data now lets investors connect physical risks to corporate earnings, credit, and valuations across entire portfolios.